Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan
· Delayed Price · Currency is JPY | Market Cap | 489.50B |
| Revenue (ttm) | 301.91B |
| Net Income (ttm) | 27.49B |
| Shares Out | 341.35M |
| EPS (ttm) | 77.39 |
| PE Ratio | 18.53 |
| Forward PE | 13.70 |
| Dividend | 38.00 (2.65%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 1,403,700 |
| Average Volume | 1,655,765 |
| Open | 1,367.00 |
| Previous Close | 1,356.50 |
| Day's Range | 1,364.50 - 1,383.00 |
| 52-Week Range | 1,348.50 - 1,878.50 |
| Beta | 0.20 |
| RSI | 42.48 |
| Earnings Date | Feb 6, 2025 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha... [Read more]
Financial Performance
Financial StatementsNews
Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript
Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 3:30 AM ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Peter ...